|
 |
Noms commerciaux |
|
|
Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires
|
|
Bileco |
Argentine |
|
Blemisin |
Turquie |
|
Blenamax |
Australie, Colombie, Malaisie |
|
Blenoxane |
Australie, Etats Unis d’Amérique |
|
Bleo-Kyowa |
Grande Bretagne |
|
Bleocell |
Allemagne |
|
Bleocin |
Arabie Saoudite, Emirats Arabes Unis , Grèce, Hongrie, Japon, Malaisie, Pérou, Pologne, Portugal, Turquie |
|
Bleocip |
Egypte, Vénézuela |
|
Bleocris |
Argentine, Chili, Pérou |
|
Bleolem |
Colombie, Mexique |
|
Bleomax |
Mexique |
|
Bleomedac |
Allemagne |
|
Bleomicina |
Chili, Colombie, Equateur, Espagne, Italie, Mexique, Pérou |
|
Bleomycin |
Allemagne, Australie, Autriche, Danemark, Etats Unis d’Amérique, Finlande, Grande Bretagne, Hongrie, Iran, Islande, Norvège, Pays bas, Pologne, Roumanie, Suède |
|
Bleomycine |
Belgique, Canada, France, Irlande, Luxembourg, Malaisie, Maroc, Nouvelle Zélande, Suisse, Tunisie |
|
Bleomycine A |
Danemark |
|
Bleomycinum |
Allemagne |
|
Bleozen |
Pérou |
|
Blexit |
Chili |
|
Blocamicina |
Argentine |
|
Bloicin |
Egypte, Pérou |
|
Blomindex |
Mexique |
|
Blucin |
Maroc |
|
DBL Bleomycin |
Malaisie, Nouvelle Zélande |
|
Ifabec |
Mexique |
|
Lyoble |
Pérou |
|
Nikableocina |
Chili |
|
Oncobleocin |
Colombie |
|
|
 |
 |
Bibliographie : Bleomycin sulfate |
|
|
Type |
Source |
| 3 |
Revue |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 81 |
Revue |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Revue |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Revue |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
Revue |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Revue |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 248 |
Revue |
Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304. |
| 249 |
Revue |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 252 |
Revue |
Koberda M, Zieske PA, Raghavan NV, Payton RJ.
Stability of bleomycin sulfate reconstituted in 5% dextrose injection or 0.9% sodium chloride injection stored in glass vials or polyvinyl chloride containers.
Am J Hosp Pharm 1990 ; 47: 2528-2529. |
| 307 |
Revue |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 334 |
Revue |
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992. |
| 335 |
Revue |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 492 |
Revue |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 905 |
Revue |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 1410 |
Revue |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1423 |
Revue |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 3128 |
Laboratoire |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013 |
| 3420 |
Revue |
El Kateb N, Chaussard M, Bellenger P, Petit A, Faure P.
Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology
J Oncol Pharm Practice 2014 ; 21, 3: 178-187. |
| 3578 |
Laboratoire |
Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011 |
| 3644 |
Laboratoire |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3646 |
Laboratoire |
Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2013 |
| 4154 |
Laboratoire |
Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018 |
| 4471 |
Laboratoire |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019 |
|
|
